rs231775 CTLA4
Homozygous risk allele (G). Associated with: Alopecia areata; Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency; Autoimmune thyroid disease
What is rs231775?
rs231775 is a single-nucleotide polymorphism (SNP) in the CTLA4 gene. Each person carries two copies, one from each parent, so a result is reported as a pair of letters such as GG. The table below describes what studies associate with each genotype; the association is statistical, across populations, and is not a diagnosis.
What does each rs231775 genotype mean?
| Genotype | Association | What the evidence says | Confidence |
|---|---|---|---|
| GG | elevated | Homozygous risk allele (G). Associated with: Alopecia areata; Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency; Autoimmune thyroid disease | 65% |
Which drugs have annotations for rs231775?
PharmGKB clinical annotations (level 1A is the strongest evidence, 4 the weakest):
| Drug | Annotation type | Evidence level |
|---|---|---|
| cyclosporine | Toxicity | 3 |
| Antiinflammatory agents | Toxicity | 3 |
| non-steroids | Toxicity | 3 |
Is rs231775 on 23andMe and AncestryDNA chips?
Chip coverage is not recorded for this variant. Orviva reports it when a raw-data file contains it directly or via a well-correlated proxy SNP, and says so when it does not.
Sources
- PharmGKB:3
- Drug:cyclosporine
- Type:Toxicity
Upload your 23andMe, AncestryDNA or WeGene raw file → · Ask G2: “What is my genotype at rs231775 and what does it mean for me?”
Genetic associations describe risk across populations, not a diagnosis for any one person. Most variants shift risk modestly and act alongside lifestyle, environment and other genes. Consumer DNA chips do not read every position and can be wrong at any single one. For general education only; talk to a clinician or genetic counsellor before acting on anything here, and never change a prescribed medicine without your prescriber.